Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm really surprised that we didn't see a decent spike in the share price after today's RNS.
We are well used to reading woolly RNS's about this distribution deal or that partnership agreement somewhere in the world all promising jam tomorrow.
Today's RNS seemed a bit different as Opti are apparently claiming a medical breakthrough in the treatment of high blood pressure or hypertension....what's not to like about that?
If the claims of using LP(LDL) are to be believed or proven to be correct then we are on to a winner here.
Maybe the medical sample of 40 people is deemed too small to claim it as proven, but it does look like quite a compelling story here.
I think the boss needs to begin another charm offensive and do the rounds of the TV, Online and printed press extolling the benefits of LP(LDL) both from a medical and financial point of view.
13 days 7 hours and 47 minutes TO GO
H&B
LSE is not the only source of an RNS. Just go to the London stock exchange website instead or subscribe to a free service like InvestEgate.
Goetz note maintains 97p price target. Talks of H&B as a global player.
"Clinical validation differentiates SlimBiome in the heavily fragmented dietary weight
management market. We expect revenues from SlimBiome to reach approximately £1m
in FY2020E, which we believe is conservative, and >£11m by 2024E, driven by growing
sales of existing deals and new deals. Critically, products sold under the agreement are
sold under SlimBiome branding which, in the fiercely competitive retail market, helps
to raise the profile of SlimBiome, reinforcing a positive association for consumers, and
provides the potential to grow brand loyalty. A strong brand will also be critical for further
geographic expansion by OPTI into markets such as China where western brands are high
in demand and copycats are likely to flood the low end of the market."
Positive and cleverly engineered deal here. Large financial benefits likely to come in due course.
Market will react in time, clever and patient investors will share in the companies success.
08 January 2020
OptiBiotix Health Plc
("OptiBiotix" or the "Company")
Human study shows formulation with LP(LDL) (R) reduces high blood pressure
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), in partnership with Nutrilinea Srl. ("Nutrilinea") has completed a successful human study for a new food supplement formulation containing LP(LDL) (R) and has shown the product can reduce high blood pressure (hypertension).
The study was part of an agreement (RNS: 20 May 2019) with Nutrilinea to fund the development, manufacture, and carrying out of human studies for a new blood pressure product in return for 12 months exclusivity from the date the data was made available from the human study (18 December 2019) for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe.
The three month study of 40 patients was carried out by the Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and showed statistically significant reductions in both systolic, diastolic blood pressure levels, and cholesterol levels. The results of this study are consistent with ProBiotix's initial study conducted at the University of Reading which showed a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LP(LDL) (R) (Costabile et al., 2017).
The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to "dramatically reduce" a person's lifetime risk of cardiovascular disease. Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms has led doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 million in the US.
https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says
Steve Prescott, Chief Executive Officer of ProBiotix, commented: "We are very pleased to have partnered with Nutrilinea who covered the cost of the product development, manufacturing, and the human study. Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension. Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome(R) and CholBiome(R) x3, allows ProBiotix to offer a b
Why can I never access the Opti Rns on LSE? Can access everyone else's.
Too right hobi up up and away.
They’ve found it. Grab what you can this is going to be a monster! Dyor imho.
I didn’t know that it’s extremely rare to find a natural product that reduces blood pressure. Highly desirable ip, and product to sell. Practically unique.
Can't access the RNS again. What is the content?
It will probably greet it with a share price fall as usual!
But yes it is great news.
amazed I'm the first to post this morning - the RNS is spectacular! Instead of the usually supplier deals etc etc yawn yawn, we have scientific evidence of LPLDL doing something additional...and highly desirable.
(but the market may greet it with the habitual lukewarm response...at least until it realises the implications)
Dependant on retailer home brand or OPTI own.
Circa 20% to 25% margins I believe on retail products.
As always your informative posting makes it crystal clear.
And why I think some peoples perspective and understanding is misguided.
https://lemminginvestors.blogspot.com/2020/01/optibiotix-health-h-slimbiome-launch.html
Is it me, or are people missing the scale of this deal? As a modest example. If 1000 stores sell 10 items per week for one year at £20 a pop, that's £10.4m turnover on one product. What % do OPTI get?
Yes i know Mr B thats why i got in at the bottom good luck
If this finishes flat today it just goes to show How worked the share price can be.
Always were going to see the traders exit and try and grab whatever they could. No loss in my books, however a new range is just opening up in over a thousand new locations with the rns stating this is just the beginning. Quality product backed with real science aimed to ko boom bod and other snake oil slimming compounds. We know our products sell well and each sell brings in a royalty payment, some at up to four stages of the sales program. An excellent day for sure.
looks interesting here i can see a bounce on the way
Same here, but I use investegate, never fails.
https://www.investegate.co.uk/Index.aspx?searchtype=3&words=OPTI
I'm getting the same on a PC.
Every time we get an RNS The price dips to clear out the weak and nervous investors. It’s always been a sit tight and wait and will be for a little while yet .